In a filing, Cidara Therapeutics Inc revealed its CHIEF SCIENTIFIC OFFICER Tari Leslie unloaded Company’s shares for reported $14085.0 on Mar 11 ’24. In the deal valued at $0.67 per share,21,029 shares were sold. As a result of this transaction, Tari Leslie now holds 258,681 shares worth roughly $0.19 million.
Then, Sandison Taylor sold 20,662 shares, generating $13,839 in total proceeds. Upon selling the shares at $0.67, the Chief Medical Officer now owns 347,095 shares.
Before that, Ward Shane sold 20,473 shares. Cidara Therapeutics Inc shares valued at $13,713 were divested by the COO & CLO at a price of $0.67 per share. As a result of the transaction, Ward Shane now holds 198,770 shares, worth roughly $0.15 million.
A number of analysts have revised their coverage, including WBB Securities’s analysts, who increased its forecast for the stock in late September from “a Buy” to “a Strong buy”. Aegis Capital began covering CDTX with “Buy” recommendation on March 04, 2021. Wedbush revised its rating on September 04, 2019. It rated CDTX as “an Outperform” which previously was an “a Neutral”.
Price Performance Review of CDTX
On Tuesday, Cidara Therapeutics Inc [NASDAQ:CDTX] saw its stock fall -11.48% to $0.73. Over the last five days, the stock has lost -16.57%. Cidara Therapeutics Inc shares have fallen nearly -8.06% since the year began. Nevertheless, the stocks have fallen -32.41% over the past one year. While a 52-week high of $1.48 was reached on 04/03/24, a 52-week low of $0.59 was recorded on 02/01/24. SMA at 50 days reached $0.7696, while 200 days put it at $0.8439. A total of 1.26 million shares were traded, compared to the trading of 0.31 million shares in the previous session.
Levels Of Support And Resistance For CDTX Stock
The 24-hour chart illustrates a support level at 0.6567, which if violated will result in even more drops to 0.5833. On the upside, there is a resistance level at 0.8367. A further resistance level may holdings at 0.9433. The Relative Strength Index (RSI) on the 14-day chart is 41.46, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.1535, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 92.45%. Stochastics %K at 15.50% indicates the stock is a buying.
The most recent change occurred on July 26, 2018 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $8 price target.
